Securities class-action notices have been issued against Capricor Therapeutics and certain senior executives, alleging the biotechnology company made misleading statements about Deramiocel and the clinical data supporting its Biologics License Application. Faruqi & Faruqi said the proposed class covers investors who acquired Capricor securities from December 17, 2025, through July 26, 2026, and reminded investors that September 28, 2026, is the deadline to seek appointment as lead plaintiff. The allegations center on changes to Capricor’s pre-specified statistical analysis plan without FDA agreement before the company resubmitted the Deramiocel BLA. FDA briefing documents released July 27, 2026, said the benefit-risk assessment appeared unfavorable without evidence of effectiveness. Capricor shares fell $12.70 to $7 on July 27, a decline described as 64% in the Faruqi notice and calculated as 64.5% in an earlier notice. Shares fell another $2.38, or 36%, to $4.19 on July 30 after an FDA advisory committee voted 9-3 that available evidence did not support Deramiocel’s efficacy for DMD-associated cardiomyopathy.